Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
The combination of Alpelisib and fulvestrant specifically targeted patients with advanced breast cancer with HR/HER2- and PIK3CA mutations significantly prolongs progression-free s···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：279
Koselugois a multifunctional targeted therapy drug, which can be used as a small molecule MEK inhibitor for the treatment of low-grade serous ovarian cancer, etc., and as a tyrosin···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：276
Koselugo is a targeted therapy that targets specific cancers by inhibiting the activity of key enzymes to block the growth of cancer cells.Which drugs interact with KoselugoThere a···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：311
Koselugo is a targeted therapy drug for the treatment of low-grade serous ovarian cancer, neurofibromas, etc., by inhibiting MEK protein kinase and RET tyrosine kinase activity.Wha···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：321
Koselugois an anti-cancer drug targeting MEK protein, which can successfully block cell signaling pathways and inhibit the proliferation of tumor cells, with significant and superi···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：274
Koselugo is an MEK protein-targeted anticancer agent that can effectively cut the cell signaling chain and inhibit the proliferation of tumor cells, showing excellent therapeutic e···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：292
Koselugo is an anti-cancer drug targeting MEK protein, which inhibits tumor cell proliferation by blocking cell signaling and has significant efficacy in specific cancer types.What···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：374
By targeting and inhibiting the activity of MEK protein, Koselugo effectively cuts off the signaling pathway of tumor cells, thereby inhibiting their abnormal proliferation, bringi···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：321
Koselugoinhibits tumor cell proliferation by inhibiting MEK protein activity, blocking cell signaling, and significantly improving the quality of life of patients.Are the side effe···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：277
Koselugo is a targeted therapy drug primarily used to treat a specific subtype of neurofibromatosis type 1 (NF1), known as neurofibromatosis agenesis.What are the side effects of K···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：307
Alpelisib is a drug for the treatment of HR/HER2- breast cancer, especially for patients with PIK3CA mutations; Inhibits tumor proliferation by blocking the PI3K pathway.How much d···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：279
Alpelisib for the treatment of PIK3CA-mutated HR/HER2- advanced breast cancer in combination with fulvestrant; It is the first drug to target PIK3CA mutations, which can effectivel···【more】
Article source：Captain MedicineRelease date：2024-08-22Recommended：274
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4542024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2342025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2472025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2582025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2372025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2182025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
